Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: A population-based regional Swedish cohort study

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1675-1679

  Kristensen, Lars Erik ^a,b,c   Englund, Martin ^a,d   Neovius, Martin ^e   Askling, Johan ^e   Jacobsson, Lennart T H ^f   Petersson, Ingemar F ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CHRONIC PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PENSION; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SOCIAL INSURANCE; SWEDEN; TREATMENT FAILURE; TREATMENT RESPONSE; WORK DISABILITY;

ANTI-TNF; ECONOMIC EVALUATIONS; EPIDEMIOLOGY; PSORIATIC ARTHRITIS; TNF-ALPHA;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; PENSIONS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SICK LEAVE; SWEDEN; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84883753184     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202229     Document Type: Article

References (24)

1. Van Der Linden S, Van Der Heijde D. Spondyloarthropathies. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley's textbook of rheumatology. Philadelphia: W.B. Saunders Company, 2001:1039-53.
2. Haglund E, Bremander AB, Petersson IF, et al. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011;70:943-8.
3. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics 2008;26:121-9.
4. Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis-a systematic review. Rheumatology (Oxford) 2011;51:275-83.
5. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9. (Pubitemid 44749786)
6. Verstappen SM, Watson KD, Lunt M, et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:1570-7.
7. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
8. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
9. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64:(Suppl 2):ii78-82. (Pubitemid 40288529)
10. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
11. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
12. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
13. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
14. Neovius M, Simard J, Sundstrom A, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: covarage of the Swedish Biologic Register. Ann Rheum Dis 2011;70:516-19.
15. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
16. Dougados M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
17. Kristensen LE, Gülfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9. (Pubitemid 351281272)
18. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
19. Helliwell P, Marchesoni A, Peters M, et al. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991;30:339-45.
20. Ekdahl C, Eberhardt K, Andersson SI, et al. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
21. Kristensen LE, Petersson IF, Geborek P, et al. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford) 2012;51:243-9.
22. Strömbeck B, Jacobsson LT, Bremander A, et al. Patients with ankylosing spondylitis have increased sick leave-a registry-based case-control study over 7 yrs. Rheumatology (Oxford) 2009;48:289-92.
23. Kristensen LE, Kapetanovic MC, Gülfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:495-9.
24. Krishnan E, Fries JF. Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther 2004;6:41-4. (Pubitemid 38444460)